Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 Clinical Trial

Official title:
A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma

Status Withdrawn

Clinical Trial Summary

This phase I trial studies the side effects and best dose of talimogene laherparepvec and to see how well it works in treating patients with non-muscle invasive bladder transitional cell carcinoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Transitional Cell
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

Clinical Trial Details

NCT number	NCT03430687
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Withdrawn
Phase	Phase 1
Start date	June 1, 2018
Completion date	December 31, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02844816` - Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer	Phase 2